Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16634768 | 0.94 | ESR2 (0.44) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL25228696 | 0.87 | HDAC1 (0.43) | MAPTMEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL15651582 | 0.86 | NOTUM (0.59) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL8204675 | 0.84 | MAPT (0.47) | MAPTMEN1KMT2ATAAR1HPGD | |
| SCHEMBL8204673 | 0.84 | MAPT (0.47) | MAPTMEN1KMT2ATAAR1HPGD | |
| SCHEMBL15652274 | 0.80 | NOTUM (0.59) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL19643320 | 0.80 | ESR2 (0.43) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL29590724 | 0.79 | NR1H2 (0.69) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL14101204 | 0.79 | NR1H2 (0.69) | ESR1ESR2MAPTMEN1KMT2A | |
| SCHEMBL1648634 | 0.79 | ESR2 (0.68) | ESR1ESR2MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115297861-B | Compounds and uses thereof | 福宏治疗公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-111491939-B | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-116133658-A | Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same | 株式会社 钟根堂 | 2023-05-16 | — | — | CN | disclosed |
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-11 | — | — | US | disclosed |
| EP-4096667-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-110938076-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-08-10 | — | — | CN | disclosed |
| WO-2021155320-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-112898308-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-110759916-B | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-111491939-A | Immunoproteasome inhibitors | 普林斯匹亚生物制药公司 | 2020-08-04 | — | — | CN | disclosed |
| CN-110938076-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-03-31 | — | — | CN | disclosed |
| CN-110759916-A | Pyrrolopyrimidines as TLR7 agonists | 正大天晴药业集团股份有限公司 | 2020-02-07 | — | — | CN | disclosed |
| US-6200978-B1 | FOR PREVENTING OR TREATING INFLAMMATORY DISEASES SUCH AS ARTHRITIS, PSORIASIS, ASTHMA, OR INFLAMMATORY BOWEL DISEASE, DISORDERS OF RESPIRATORY FUNCTION, GASTROINTESTINAL DISORDERS SUCH AS FUNCTIONAL BOWEL DISEASE, AS ANALGESICS | PFIZER INC. | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145003-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | ESR1 3083/4885ESR2 1378/4885MAPT 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.